Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review

Th1-like Treg in vitiligo: An incompetent regulator in immune tolerance

MicroRNA‑155 inhibits the proliferation of CD8+ T cells via upregulating regulatory T cells in vitiligo

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection

Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications

Vitiligo: A focus on pathogenesis and its therapeutic implications

Advances in vitiligo: Update on therapeutic targets

The role of aryl hydrocarbon receptor in vitiligo: a review

Polyphenols targeting multiple molecular targets and pathways for the treatment of vitiligo

MIF Inhibition Alleviates Vitiligo Progression by Suppressing CD8+ T Cell Activation and Proliferation

Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

1205 MIF-inhibition Ameliorates Vitiligo by Suppressing CD8+T Cell Activation and Proliferation

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

HO-1 regulates the function of Treg: Association with the immune intolerance in vitiligo

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

MicroRNAs: Emerging Players in the Pathogenesis of Vitiligo

Vitiligo: From Pathogenesis to Treatment

The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment

The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy